Tirzepatide

What is Tirzepatide? Tirzepatide is a dual-agonist research peptide: a single 39-residue backbone engineered to activate both incretin receptors, GLP-1 and GIP. Engaging two receptors with one molecule made it a reference compound in metabolic-pathway research — and the benchmark against which newer multi-receptor designs are read. ## Why researchers choose it For work on convergent signalling, one dual-active input beats co-administering two single agonists: the readout reflects combined receptor activity under a single, defined kinetic profile. A fatty-acid side chain extends serum half-life to a duration measured in days, keeping protocols clean of frequent re-administration artifacts. Supplied as lyophilized powder in 30 mg and 60 mg vials. ## The REPRIME standard Synthesising 39 residues cleanly is the hard part — deletion sequences co-elute close to the target — so the evidence matters. Every batch is independently HPLC-tested and released at ≥99% main-peak purity, with the COA and chromatogram published before you order. Each vial ships cold-chain with a unique REP-XXXX-XXXX-X code; the first scan confirms authenticity. For laboratory and research use only; not for human consumption.